\-\ Texto\\:\\ \ \(0\)\
\-\ right\\ proptosis\ \(4\)\
\-\ conservative\\ rx\\ or\\ xrt\ \(0\)\
\-\ \\â\\€\\¢\\ right\\ optic\\ nerve\\ mass\\ which\\ is\\ isointense\\ on\\ t1\\ and\\ t2\\.\\ \\ \ \(0\)\
\-\ \\â\\€\\¢\\ a\\ peripheral\\ rim\\ of\\ t2\\ bright\\ signal\\ may\\ be\\ secondary\\ to\\ nerve\\ sheath\\ dilatation\\ \\(csf\\ intensity\\)\\ or\\ in\\ the\\ setting\\ of\\ nf1\\,\\ this\\ finding\\ may\\ correspond\\ to\\ arachnoidal\\ gliomatosis\\.\ \(0\)\
\-\ \\â\\€\\¢\\ intense\\ enhancement\\.\ \(0\)\
\-\ \\â\\€\\¢\\ cannot\\ distinguish\\ mass\\ from\\ optic\\ nerve\\.\ \(0\)\
\-\ optic\\ glioma\ \(7\)\
\-\ \\â\\€\\¢\\ optic\\ nerve\\ glioma\\ \\(astrocytoma\\)\ \(0\)\
\-\ \\Â\\»\\ much\\ less\\ likely\ \(1\)\
\-\ \\â\\€\\¢\\ meningioma\ \(7\)\
\-\ \\â\\€\\¢\\ hemangioma\ \(0\)\
\-\ \\â\\€\\¢\\ schwannoma\ \(0\)\
\-\ 2\\ y\\/o\\ boy\\ with\\ right\\ proptosis\\.\ \(1\)\
\-\ of\\ note\\:\\ this\\ patient\\ also\\ had\\ nonspecific\\ t2\\/flair\\ white\\ matter\\ hyperintensities\\.\\ \\ in\\ the\\ setting\\ of\\ optic\\ nerve\\ glioma\\,\\ these\\ may\\ represent\\ nf\\ bodies\\ \\(focal\\ areas\\ of\\ signal\\ intensity\\)\\.\\ \\ further\\ history\\ and\\ physical\\ exam\\ findings\\ are\\ pending\\ to\\ see\\ if\\ patient\\ meets\\ nf1\\ criteria\\.\ \(0\)\
\-\ neurofibromatosis\\ 1\\:\\ \\ criteria\\:\\ \\ \ \(0\)\
\-\ \\(2\\ or\\ more\\ of\\ following\\)\ \(1\)\
\-\ 6\\ or\\ more\\ caf\\?\\ au\\ lait\\ spots\ \(1\)\
\-\ 2\\ or\\ more\\ lisch\\ nodules\\ \\(hamartoma\\ of\\ iris\\)\ \(0\)\
\-\ 2\\ or\\ more\\ neurofibromas\\ or\\ 1\\ plexiform\\ nf\ \(1\)\
\-\ axillary\\/inguinal\\ freckling\ \(1\)\
\-\ 1\\ or\\ more\\ bone\\ dysplasia\\ or\\ pseudoarthrosis\\ of\\ long\\ bone\ \(1\)\
\-\ optic\\ pathway\\ glioma\ \(1\)\
\-\ 1st\\ degree\\ relative\\ with\\ nf\\-1\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ optic\\:\\ 0\\.09889265049012065\ \(0\)\
\-\ \\-2\\:\\ 0\\.07716906135298389\ \(0\)\
\-\ glioma\\:\\ 0\\.07705347587413182\ \(0\)\
\-\ nerve\\:\\ 0\\.07697365316218266\ \(0\)\
\-\ nf\\:\\ 0\\.06869608274911185\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.06268057406383551\ \(0\)\
\-\ nf1\\:\\ 0\\.05982305079910282\ \(0\)\
\-\ more\\:\\ 0\\.05342940773280416\ \(0\)\
\-\ proptosis\\:\\ 0\\.04772467156131948\ \(0\)\
\-\ criteria\\:\\ 0\\.04672383697574966\ \(0\)\
\-\ or\\:\\ 0\\.045068523703366836\ \(0\)\
\-\ arachnoidal\\:\\ 0\\.04407759211983249\ \(0\)\
\-\ \\-axillary\\/inguinal\\:\\ 0\\.04407759211983249\ \(0\)\
\-\ \\-1st\\:\\ 0\\.04407759211983249\ \(0\)\
\-\ setting\\:\\ 0\\.04315708753636233\ \(0\)\
\-\ \\-6\\:\\ 0\\.04061185621703277\ \(0\)\
\-\ au\\:\\ 0\\.038584530676491945\ \(0\)\
\-\ lait\\:\\ 0\\.038584530676491945\ \(0\)\
\-\ freckling\\:\\ 0\\.038584530676491945\ \(0\)\
\-\ \\-1\\:\\ 0\\.038584530676491945\ \(0\)\
\-\ \\-optic\\:\\ 0\\.038584530676491945\ \(0\)\
\-\ meets\\:\\ 0\\.03714612031423304\ \(0\)\
\-\ caf\\:\\ 0\\.03714612031423304\ \(0\)\
\-\ lisch\\:\\ 0\\.03714612031423304\ \(0\)\
\-\ iris\\:\\ 0\\.03603040255766199\ \(0\)\
\-\ gliomatosis\\:\\ 0\\.034348041374555924\ \(0\)\
\-\ t2\\/flair\\:\\ 0\\.034348041374555924\ \(0\)\
\-\ nf\\-1\\:\\ 0\\.034348041374555924\ \(0\)\
\-\ plexiform\\:\\ 0\\.03309146923315139\ \(0\)\
\-\ pseudoarthrosis\\:\\ 0\\.03309146923315139\ \(0\)\
\-\ rx\\:\\ 0\\.03165305887089249\ \(0\)\
\-\ neurofibromas\\:\\ 0\\.03165305887089249\ \(0\)\
\-\ pathway\\:\\ 0\\.03165305887089249\ \(0\)\
\-\ intensity\\:\\ 0\\.03088670676379301\ \(0\)\
\-\ correspond\\:\\ 0\\.03053734111432144\ \(0\)\
\-\ hyperintensities\\:\\ 0\\.030214648508633583\ \(0\)\
\-\ spots\\:\\ 0\\.02991152539955141\ \(0\)\
\-\ xrt\\:\\ 0\\.029098930752062536\ \(0\)\
\-\ may\\:\\ 0\\.028114925533471856\ \(0\)\
\-\ distinguish\\:\\ 0\\.026023002556611368\ \(0\)\
\-\ t2\\:\\ 0\\.02418588768750352\ \(0\)\
\-\ neurofibromatosis\\:\\ 0\\.02360586930872199\ \(0\)\
\-\ sheath\\:\\ 0\\.023523222798965935\ \(0\)\
\-\ hamartoma\\:\\ 0\\.02336191848787483\ \(0\)\
\-\ intense\\:\\ 0\\.022625294914090537\ \(0\)\
\-\ signal\\:\\ 0\\.022530743302727786\ \(0\)\
\-\ nonspecific\\:\\ 0\\.0219833890808495\ \(0\)\
\-\ bright\\:\\ 0\\.021361118208482473\ \(0\)\
\-\ bone\\:\\ 0\\.0212343468145987\ \(0\)\
\-\ \\Â\\»\\:\\ 0\\.02105174118989203\ \(0\)\
\-\ isointense\\:\\ 0\\.021001989535626195\ \(0\)\
\-\ relative\\:\\ 0\\.020352931478016242\ \(0\)\
\-\ 1\\:\\ 0\\.02033326367959707\ \(0\)\
\-\ bodies\\:\\ 0\\.020016670342970402\ \(0\)\
\-\ degree\\:\\ 0\\.020016670342970402\ \(0\)\
\-\ much\\:\\ 0\\.01977853009802413\ \(0\)\
\-\ schwannoma\\:\\ 0\\.019514317691152232\ \(0\)\
\-\ hemangioma\\:\\ 0\\.019091530751011915\ \(0\)\
\-\ represent\\:\\ 0\\.01876461695469766\ \(0\)\
\-\ pending\\:\\ 0\\.018487623057748717\ \(0\)\
\-\ 2\\:\\ 0\\.018401044965105463\ \(0\)\
\-\ dilatation\\:\\ 0\\.018311134147343595\ \(0\)\
\-\ rim\\:\\ 0\\.018085106963503364\ \(0\)\
\-\ \\(\\:\\ 0\\.018059043156096515\ \(0\)\
\-\ csf\\:\\ 0\\.01784247175903006\ \(0\)\
\-\ \\)\\:\\ 0\\.017838442302832627\ \(0\)\
\-\ nodules\\:\\ 0\\.017712594327013758\ \(0\)\
\-\ conservative\\:\\ 0\\.017064205210471094\ \(0\)\
\-\ \\:\\:\\ 0\\.016954122239859974\ \(0\)\
\-\ dysplasia\\:\\ 0\\.016865503567223522\ \(0\)\
\-\ matter\\:\\ 0\\.01682239985200399\ \(0\)\
\-\ \\?\\:\\ 0\\.016674397503122534\ \(0\)\
\-\ astrocytoma\\:\\ 0\\.01659175099336648\ \(0\)\
\-\ note\\:\\ 0\\.016490327637508954\ \(0\)\
\-\ meningioma\\:\\ 0\\.016430446682275376\ \(0\)\
\-\ peripheral\\:\\ 0\\.015459666610070586\ \(0\)\
\-\ long\\:\\ 0\\.014731107554163618\ \(0\)\
\-\ boy\\:\\ 0\\.014523608899629857\ \(0\)\
\-\ less\\:\\ 0\\.014469700021613413\ \(0\)\
\-\ areas\\:\\ 0\\.014376735856230335\ \(0\)\
\-\ white\\:\\ 0\\.01417052106356009\ \(0\)\
\-\ finding\\:\\ 0\\.013770307525192408\ \(0\)\
\-\ further\\:\\ 0\\.01358722070900129\ \(0\)\
\-\ t1\\:\\ 0\\.01354247768112122\ \(0\)\
\-\ right\\:\\ 0\\.01352447563665625\ \(0\)\
\-\ see\\:\\ 0\\.012751086056143942\ \(0\)\
\-\ focal\\:\\ 0\\.01220246802069201\ \(0\)\
\-\ following\\:\\ 0\\.012126388784505742\ \(0\)\
\-\ likely\\:\\ 0\\.012051449829678283\ \(0\)\
\-\ secondary\\:\\ 0\\.011945149832544038\ \(0\)\
\-\ mass\\:\\ 0\\.011884610069475646\ \(0\)\
\-\ y\\/o\\:\\ 0\\.011833145149098204\ \(0\)\
\-\ if\\:\\ 0\\.011593717168903178\ \(0\)\
\-\ enhancement\\:\\ 0\\.01145244383061518\ \(0\)\
\-\ these\\:\\ 0\\.0111192234597892\ \(0\)\
\-\ physical\\:\\ 0\\.010482526347906192\ \(0\)\
\-\ can\\:\\ 0\\.009691111762345349\ \(0\)\
\-\ this\\:\\ 0\\.009611372133141331\ \(0\)\
\-\ exam\\:\\ 0\\.00938616969974769\ \(0\)\
\-\ had\\:\\ 0\\.009219249096203542\ \(0\)\
\-\ findings\\:\\ 0\\.009094184678949799\ \(0\)\
\-\ patient\\:\\ 0\\.00856591930916388\ \(0\)\
\-\ also\\:\\ 0\\.008423097968350756\ \(0\)\
\-\ which\\:\\ 0\\.007975722936212744\ \(0\)\
\-\ be\\:\\ 0\\.006588783616719646\ \(0\)\
\-\ to\\:\\ 0\\.006406021626644794\ \(0\)\
\-\ from\\:\\ 0\\.006332178565771062\ \(0\)\
\-\ not\\:\\ 0\\.006174093358709677\ \(0\)\
\-\ history\\:\\ 0\\.005901072688535417\ \(0\)\
\-\ are\\:\\ 0\\.005824369362648009\ \(0\)\
\-\ of\\:\\ 0\\.004660152031919537\ \(0\)\
\-\ in\\:\\ 0\\.0042139723014025495\ \(0\)\
\-\ on\\:\\ 0\\.0036194550618271404\ \(0\)\
\-\ is\\:\\ 0\\.002811453891923628\ \(0\)\
\-\ \\,\\:\\ 0\\.002707100655172874\ \(0\)\
\-\ a\\:\\ 0\\.0019829990090930063\ \(0\)\
\-\ and\\:\\ 0\\.0018000900573221846\ \(0\)\
\-\ \\.\\:\\ 0\\.001419981443893851\ \(0\)\
\-\ the\\:\\ 0\\.001382492847036258\ \(0\)\
\-\ with\\:\\ 0\\.0011700417608988974\ \(0\)\
